The Acute and Chronic Haemodynamic Effects of Prazosin in Severe Congestive Cardiac Failure

Harper, Richard W.; Claxton, Heather; Middlebrook, Ken; Anderson, S.; Pitt, Aubrey

doi:10.5694/j.1326-5377.1980.tb125810.x

Cited by 32 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An inflated functional improvement attributed to therapy with -antagonists could have resulted. The improvements ascribed to -antagonists could also have been in¬ flated by including the three studies81, 33,40 with symptom scales other than the New York Heart Association criteria.…”

Section: Resultsmentioning

confidence: 99%

“…All studies reported deaths, and all but one15 reported functional sta¬ tus changes. Functional changes were assessed using New York Heart Associ-ation criteria in 22 studies and using similar symptom scales in five others a., 31,33,39,40 Exercise data were nfjt pooled because exercise capacity was assessed with eight different exercise protocols and four different response measurements.…”

mentioning

confidence: 99%

“…As crossover trials are subject to period intervention interactions, mor¬ tality and functional status effect mea¬ sures were also determined without in¬ cluding data from these studies. 30,35,37,40 Functional status was further examined without including data from the five tri¬ als29,31,33,39,40 that used symptom scales other than the New York Heart Associ¬ ation scale. In these analyses, effects again had the same direction, the same relative ranking, and the same statisti¬ cal significance as in the original analyses.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Relative Efficacy of Vasodilator Therapy in Chronic Congestive Heart Failure

Mulrow

Linn

et al. 1988

JAMA

View full text Add to dashboard Cite

We examined existing evidence concerning the relative efficacy of various vasodilator agents in chronic congestive heart failure. Only randomized placebo-controlled trials with clinical end points and treatment durations of four weeks or more were selected from an exhaustive search of the English-language medical literature. Twenty-eight trials involving 1976 patients were found. Treatment durations of the trials varied from one month to two years. Patients with symptomatic heart failure despite digitalis and diuretic therapy were studied; most were middle-aged men and approximately half had coronary artery disease. Results of the trials were appraised by three independent observers, and mortality and functional status outcomes were pooled in a meta-analysis. All vasodilator agents except hydralazine hydrochloride were associated with improvements in functional status. Angiotensin converting-enzyme inhibitors were the only agents associated with both decreased mortality (odds ratio, 0.51; 95% confidence interval, 0.34 to 0.75) and improved functional status (odds ratio, 4.53; 95% confidence interval, 3.46 to 5.92). The optimal timing for initiation of these agents was not established.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Relative Efficacy of Vasodilator Therapy in Chronic Congestive Heart Failure

Mulrow

Linn

et al. 1988

JAMA

View full text Add to dashboard Cite

show abstract

“…4 After initial promising reports in acute and chronic congestive heart failure' 2 several investigators have reported tachyphlaxis during acute studies using continuous haemodynamic monitoring.5 6 The relevance of this acute phenomenon to chronic ambulatory treatment is uncertain, since other investigators have reported sustained benefit during chronic ambulatory treatment.2 7 8 Drug tolerance during chronic prazosin treatment has been described less frequently." 10 Long-term controlled studies with a large study population will eventually *Supported in part by the Herman C Krannert Fund; and by grants from the National Heart, Lung and Blood Institute of the National Institutes of Health.…”

mentioning

confidence: 99%